 | Info Sheets |
| | | | | | | | | | | | | | | | | | | | | | | | |
 | Out- side |
| | | | |
|
| | | | |
Result : Searchterm 'Relaxation Effect' found in 1 term [ ] and 3 definitions [ ], (+ 17 Boolean[ ] results
| previous 6 - 10 (of 21) nextResult Pages : [1] [2 3 4 5] |  | |  | Searchterm 'Relaxation Effect' was also found in the following service: | | | | |
|  |  |
| |
|
| |  | | | | | | | Further Reading: | | Basics:
|
|
News & More:
| |
| |
|  | |  |  |  |
| |
|
| | | |  | | • View the DATABASE results for 'Fluid Attenuation Inversion Recovery' (5).
| | | | Further Reading: | Basics:
|
|
News & More:
| |
| |
|  | |  |  |  |
| |
|
(Gd) Gadolinium is a Lanthanide element that is paramagnetic in its trivalent state.
This paramagnetic substance is used for MR imaging because of the effect of strongly decreasing the T1 relaxation times of the tissues to which gadolinium has access. When injected during magnetic resonance imaging, gadolinium will tend to change signal intensities by shortening the T1 time in its surroundings.
The relaxivity of gadolinium is an important measure of its efficacy, which is dependent on the chemical properties of the complex. The gadolinium ion cannot be used in its chloride, sulfate, or acetate forms because of poor tolerance and low solubility in water in the neutral pH range. Although toxic by itself, gadolinium can be given safely in a chelated form such as DTPA, that still retains much of its strong effect on relaxation times ( relaxivity).
See also Dotarem®, Gadovist®, MultiHance®, Omniscan®, OptiMARK®, and Contrast Agents, the info sheet gives an overview and more in-dept information about different types of MRI contrast agents. | | | |  | | • View the DATABASE results for 'Gadolinium' (66).
| | | • View the NEWS results for 'Gadolinium' (17).
| | | | Further Reading: | Basics:
|
|
News & More:
| |
| |
|  |  | Searchterm 'Relaxation Effect' was also found in the following service: | | | | |
|  |  |
| |
|
(IRSE) Form of inversion recovery imaging in which the signal is detected as a spin echo. For TE short compared to the T2 relaxation time, there will be only a small effect of T2 differences on image intensities; for longer TE's, the effect of T2 may be significant. | |  | | | Further Reading: | Basics:
|
|
| |
|  | |  |  |  |
| |
|
(Mn-DPDP) This agent, mangafodipir trisodium, is a hepatocyte specific MRI contrast agent. Manganese is very toxic, so it has to be chelated and put in the form of a vitamin B6 analog, which is taken up by normal hepatocytes to some extent.
Teslascan® was developed in the early 1980's, went through clinical trials in the early 1990's, and was approved in 1997. One problem with assessing the efficacy of this agent is the fact that the phase III trials finished in the early 1990's, and the techniques used for MR today are very different from the techniques used almost a decade ago.
This contrast agent shortens the T1 relaxation time. On T1 weighted pictures it makes a normal liver look brighter. Since metastases, for example, do not generally take up this agent, the contrast between the enhancing liver and the non-enhancing lesions will increase on T1 weighted pictures. It does not have much effect on T2 weighted images.
Drug Information and Specification T1, Predominantly positive enhancement PHARMACOKINETIC Hepatobiliary, pancreatic, adrenal DOSAGE 5 µmol/kg, 0.5 ml/kg PREPARATION Finished product DEVELOPMENT STAGE Approved PRESENTATION Vials of 100 ml DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information TERRITORY TRADE NAME DEVELOPMENT STAGE DISTRIBUTOR | |  | | • View the DATABASE results for 'Teslascan®' (4).
| | | | Further Reading: | Basics:
|
|
News & More:
| |
| |
|  | |  |  |
|  | | |
|
| |
 | Look Ups |
| |